

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necessary)

Sheet 1 of 5

Complete if Known						
Application Number 10/591,923-Conf. #5393						
Filing Date	September 5, 2006					
First Named Inventor	Daniel J. Rader					
Art Unit	1614					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	AGP-002					

		Y	U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevan Figures Appear
/K.W./	A 4 8	US-20020035064-A1	03-21-2002	Robl et al.	- golden Appare
5	A2*	US-20020045271-A1	04-18-2002	Hussain et al.	
<u> </u>	A3°	US-20030069221-A1	04-10-2002	Kosoglou et al.	
	A4*	US-20030009221-A1	06-12-2003	Ogletree	
<del></del>	A5*	US-20030162788-A1	08-28-2003	Thomas et al.	
- <del>{</del>	A6*	US-20030187053-A1	04-13-2004	Bertinato et al.	
	A7*	US-20040014748-A1	01-22-2004	Grutzmann et al.	
<u>§</u>	A8*	US-20040014746-A1	03-25-2004	Keller et al.	
<b>-</b>	A9*	US-20040036906-A1	04-07-2005	Hagiwara et al.	
			04-07-2005	Blumberg	
<del> </del>		US-20050090426-A1	05-12-2005	Tunac	
-	A11*	US-20050101561-A1		Lee et al.	
·}		US-20060069161-A1	03-30-2006		
		US-20060135460-A1	06-22-2006	Widder et al.	
	A14*	US-20060153913-A1	07-13-2006	Yamane et al.	
_ <del>-</del>	A15*	US-20060205726-A1		Hagiwara et al.	
<u> </u>	A16*	US-20060211020-A1	09-21-2006	Farrer et al.	
	A17*	US-20060211762-A1	09-21-2006	Rongen et al.	
-		US-20060270655-A1	11-30-2006	Swick et al.	
1		US-20070088089-A1	04-19-2007	Wisler	
		US-20070093468-A1	04-26-2007	Wisler	
<b></b>	A21*	US-20070093527-A1	04-26-2007	Wisler	
		US-3,983,140	09-28-1976	Endo et al.	
		US-4,231,938	11-04-1980	Monaghan et al.	
		US-4,346,227		Terahara et al.	
		US-4,448,784	05-15-1984	Glamkowski et al.	
		US-4,450,171		Hoffman et al.	
1		US-4,499,289	02-12-1985		
		US-4,613,610	***************	Wareing	
		US-4,647,576		Hoefle et al.	
		US-4,686,237	08-11-1987	Anderson	
8		US-4,871,721	10-03-1989	Biller	
8		US-4,924,024	05-08-1990	Biller	
		US-5,117,080	05-26-1992	Lee et al.	
		US-5,595,872		Wetterau, II et al.	
		US-5,684,014		Muller et al.	
		US-5,712,279		Biller et al.	
		US-5,712,396		Magnin et al.	
		U\$-5,739,135		Biller et al.	
		US-5,760,246		Biller et al.	
		US-5,786,361		Muller et al.	
1		US-5,789,197		Wetterau, il et al.	
8		US-5,811,429		Connell et al.	
		U\$-5,827,875		Dickson, Jr. et al.	
W/		US-5,883,109_	03-16-1999		
*		US-5,885,983	03-23-1999		****
KIALL		US-5,952,498		Lenfers et al.	
17.44.	A47*	US-5,990,110	11-23-1999	Firestone	

Examiner /Kevin Weddington/ Date 10/08/2009 Considered

Subs	titute for	om 1449/PTO	······	**************************************	-			Complete if	Kno	wn	
						Appl	lication Number	10/591,92	23-0	Conf. #5393	
						Filin	g Date	Septembe	er 5	, 2006	
STATEMENT BY APPLICANT					Firet	First Named Inventor Daniel J. Rader					
					Art U		1614				
	(U	se as many she	ets as	necess ary)							
,,						EXBO	niner Name	Not Yet A	SSI	gnea	
Sheet		2	of	5		Attor	ney Docket Numbe	r AGP-002			
AK.W.	A48*	US-6,034,11	5	03-07-20	00 Coni	nell e	et al.		Τ		
8		US-6,057,33		05-02-200			***************************************				
		US-6,066,65		05-23-20							
		US-6,066,65		05-23-20					ļ		
		US-6,114,34		09-05-200					<u> </u>		,
		US-6,245,77		06-12-20					<u> </u>		
		US-6,265,43		07-24-20					<u> </u>		
		US-6,297,23		10-02-20					<u> </u>		
		US-6,344,45		02-05-20					<u> </u>		
		US-6,479,50		11-12-200					ļ		
		US-6,492,36		12-10-20			, Il et al.		<u> </u>		
		US-6,498,15		12-24-20			et al.				
<b></b>		US-6,620,82		09-16-200					ļ		
		US-6,627,63		09/20/200					<b>├</b>		
<b>  </b>		US-6,720,35		04-13-20					├		
		US-6,774,23		08-10-200 11-02-200					-		
<del></del>		US-6,812,34	- Property and the second						<b>├</b> ─		
		US-6,846,83		01-25-20							
		US-6,858,62		02-22-200					-		
		US-6,875,78							+		
-		US-6,916,80		07-12-200 07-12-200					┼		
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		US-6,916,81		09-27-20			et al.		┿		
-W-		US-6,949,57 US-6,979,69		12-27-20			et al.		<del> </del>		
		US-7,053,08		05-30-20				·	<del> </del>		
-/K.₩		US-7,056,90		06-06-20							
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	······································		·/					
ļ	<del></del>	<del></del>		FOREK			DOCUMENTS				<del></del>
Examiner	Cite	Foreign	Palent I	Document	Publicat Date	ion	Name of	Patentee or		Pages, Columns, Lines, Where Relevant Passages	١.
Initials	No.	Country Code <sup>2</sup> -Nu	ımber⁴-i∢	ind Code <sup>s</sup> (if known)	MM-DD-Y	YYY		Cited Document		Or Relevant Figures Appear	
/K.W.	/B1	EP-0142146			05-22-1	985	Merck & Co Ir	iC			T
8	B2	EP-0221025			05-06-1	987	Sandoz Ag et				T
	B3	EP-0325130			07-26-11	989	Bayer Ag		7		1
	B4	EP-0705831				فعنننت	Bayer Ag		7		ΙÌ
	B5	EP-0779276					Bayer Ag				t
<del>                                     </del>	86	EP-0779279			06-18-19		Bayer Ag				Ì
<del>  </del>	B7	EP-0719219 EP-0799828			10-08-1		Bayer Ag				╁
<del>  </del>				·	10-08-1		<del></del>			***************************************	V
<b></b>	88	EP-0802198					Bayer Ag				Ľ
<b> </b>	B9	EP-1 181 95			02-27-20		Pfizer				-
<del>                                     </del>	B10	EP-1099442			05-16-20		Pfizer Prod In				ـ
<b></b>	B11	CA-2091102			09-07-19		Squibb & Son				-
<u> </u>		GB-2205837			12-21-19		Squibb & Son	s inc		······································	ļ.,
		FR-2596393					Sanofi Sa				1
		AU-727895	-		07-23-19		Bristol Myers				L
	B15	CA-2291471			06-04-20		Pfizer Prod In				$oldsymbol{\mathbb{L}}$
W	B16	CA-2325201			05-10-20		Pfizer Prod Inc	3			
11/ 18/		DE-1995102	2		04-26-20		Bayer Ag				V
717.77	818	JP-2002-220	345		08-09-20	002	Sumitomo Ph	arma			V
Cvomic		ZZ OWIE TAVE	J.J	ta al			17	Date	47	מממכינסמעמ	-
Examine Signatur		/Kevin We	uaing	JION/				Date Considered	11	0/08/2009	
			~~~~	***************************************		***************************************					******

Complete if Known Substitute for form 1449/9TO Application Number 10/591,923-Conf. #5393 INFORMATION DISCLOSURE Filing Date September 5, 2006 STATEMENT BY APPLICANT First Named Inventor Daniel J. Rader 1614 Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 5 Attorney Docket Number AGP-002 3 /K.₩./ B19 WO-00/038725 07-06-2000 | Searle & Co et al. B20 WO-01/008679 02-08-2001 | Verkade Hendrik Jan B21 WO-04/028544 04-08-2004 | Novo Nordisk A/S B22 WO-04/110368 12-23-2004 | Merck & Co., Inc. B23 WO-04/110375 12-23-2004 Merkc & Co., Inc. B24 WO-05/000217 01-06-2005 | Merck & Co., Inc. B25 WO-05/051382 11-25-2004 Yamanouchi Pharmaceutical 08-11-2005 Japan Tobacco Inc. B26 WO-05/072740 827 WO-05/084666 09-15-2005 Abeille Pharmaceuticals B28 WO-05/094864 10-13-2005 | Max-Planck Gesellschaft Zur B29 WO-05/097131 10-25-2005 Janssen Pharmaceuetica NV B30 WO-06/046623 05-04-2006 Japan Tobacco Inc. B31 WO-06/062748 Reliant Pharmaceuticals, Inc. 06-15-2006 B32 WO-06/063128 06-15-2006 Sytera, Inc. B33 WO-06/108666 10-19-2006 Proteosys AG Merck Patent GMBH B34 WO-06/111238 10-26-2006 Aegerion Pharmaceuticals B35 WO-07/047880 04-26-2007 B36 WO-05/087234 09-22-2005 Rader **B37** WO-86/003488 06-19-1986 Sandoz Ag B38 WO-86/007054 12-04-1986 Sandoz Ag et al. B39 WO-96/026205 08-29-1996 Squibb Bristol Myers Co B40 WO-96/040640 12-19-1996 Pfizer et al. 11-06-1997 | Pfizer et al. 841 WO-97/041111 842 01-29-1998 Squibb Bristol Myers Co WO-98/003069 01-29-1998 | Squibb Bristol Myers Co B43 WO-98/003174 B44 WO-98/023593 06-04-1998 | Pfizer et al. B45 WO-98/027979 07-02-1998 | Squibb Bristol Myers Co B46 WO-98/031225 07-23-1998 | Squibb Bristol Myers Co B47 WO-98/031366 07-23-1998 | Squibb Bristol Myers Co B48 WO-98/031367 07-23-1998 | Squibb Bristol Myers Co B49 WO-98/050028 11-12-1998 | Squibb Bristol Myers Co /K.W/850 WO-07/047724 04-26-2007 Wisler

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO: Those application(s) which are marked with an single esterisk (\*) next to the Cite No, are not supplied (under 37 CFR 198(s)(2)(iii)) because that application was filled after June 30, 2003 or is available in the IFW. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

17/17/17/17/17/17/17/17/17/17/17/17/17/1		······································	
Examiner	Mayin Maddington	Date	10/00/000
0:	Wealth Aregonitatory	0	1 10/00/2009 1
12 ignature		Lonsidered	

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/591,923-Conf. #5393	
IN	<b>VFORMATION</b>	I DI	SCLOSURE	Filing Date	September 5, 2006	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Daniel J. Rader	
				Art Unit	1614	
	(Use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 4 of 5		Attorney Docket Number	AGP-002		

Citidatis No. Imagazine, journal, serial, symposium, catalog, etc.), date, page; day, volume-Issue number(s), publisher. City and/or country where published.  C. Atzel, A., et al., "Mechanism of Microsomal Triglyceride Transfer Protein Catalyzed Lipid Transport", Biochemistry (1993), 32, 10444-10450.  C. Bakillah A. et al., "Decreased Secretion of ApoB follows inhibition of ApoB-MTP Binding by a Novel Antagonist", Biochemistry (Mosc), (2000), 39(16):4892-4899.  C. Barclay, "Hyperflipidemia", NMT Briefs, 2003.  C. Bayes, M., et al., "Gateways to Clinical Trials", Methods and Findings in Experimental and Clinical Pharmacology, 24(1):2002, 37-55.  C. Bayes et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacother, 2003 Nov;4(11):1901-38.  C. Bayes et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacother, 2003 Nov;4(11):1901-38.  C. Bruckert, "New Lipid-Modifying Therapies", Expert Opin, Investig, Drugs, (2003)12(3):325-35.  C. Capson, T.L., (Ph. D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C. Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002); 5(4):562-70.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C. Carlone, C. Capper, C. Capp		······································	NON PATENT LITERATURE DOCUMENTS	-					
Transport", Biochemistry (1993), 32, 10444-10450.  C2 Bakillah A. et al., "Decreased Secretion of ApoB follows inhibition of ApoB-MTP Binding by a Novel Antagonist", Biochemistry (Mosc), (2000) 39(16):4892-4899.  C3 Barclay, "Hyperlipidemia", NMT Briefs, 2003.  C4 Bayes, M., et al., "Gateways to Clinical Trials", Methods and Findings in Experimental and Clinical Pharmacology, 24(1):2002, 37-55.  C5 Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacothery (2003) Nov.4(11):1901-38.  C6 Biller et al., "Isoprenoid (Phosphinylmethyl) Phosphonates as Inhibitors of Squalene synthetase", J. Med. Chem., 31 (10):1988, 1669-71.  C7 Bruckert, "New Lipid-Modifying Therapies", Expert Opin. Investig. Drugs, (2003)12(3):325-35.  C8 Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004, 64 (11): pp. 1181-1196.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III Report. Publication number 01-3095, 1-1-1X-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Orugs and Steatohepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolem	Initials •	Cite No.1	country where published.						
Novel Antagonist", Biochemistry (Mosc), (2000) 39(16):4892-4899.  C3 Barclay, "Hyperlipidemia", NMT Briefs, 2003.  C4 Bayes, M., et al., "Gateways to Clinical Trials", Methods and Findings in Experimental and Clinical Pharmacotory, 24(1):2002, 37-55.  C5 Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacother, 2003 Nov.4(11):1901-38.  C6 Billier et al., "Isoprenoid (Phosphinylmethyl) Phosphonates as Inhibitors of Squalene synthetase", J. Med. Chem., 31 (10):1988, 1869-71.  C7 Bruckert, "New Lipid-Modifying Therapies", Expert Opin, Investig. Drugs, (2003)12(3):325-35.  C8 Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigmis", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004, 64 (11): pp. 1181-1196.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, 1-1-1X-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell. "Drugs and Statohepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Exetimibe Coadministered with Atorvastatin or Sirruvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (9 pages).  In	K.W./  C1		Transport", Biochemistry (1993), 32, 10444-10450.						
C4 Bayes, M., et al., "Gateways to Clinical Trials", Methods and Findings in Experimental and Clinical Pharmacology, 24(1):2002, 37-55.  C5 Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacother, 2003 Nov;4(11):1901-38.  C6 Billier et al., "Isoprenoid (Phosphinylmethyl) Phosphonates as Inhibitors of Squalene synthetase", J. Med. Chem., 31 (10):1998, 1869-71.  C7 Bruckert, "New Lipid-Modifying Therapies", Expert Opin. Investig. Drugs, (2003)12(3):325-35.  C8 Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Monteliano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1196  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell, "Drugs and Steatchepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezettimibe Coadministered with Atorvastatin or Sirruvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (9 pages).  C18 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C19 International	000ctroposts	C2		Annonnous de la constante de l					
Cinical Pharmacology, 24(1):2002, 37-55.  Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacother, 2003 Nov,4(11):1980-38.  C6 Biller et al., "Isoprenoid (Phosphinylmethyl) Phosphonates as Inhibitors of Squalene synthetase", J. Med. Chem., 31 (10):1988, 1869-71.  C7 Bruckert, "New Lipid-Modifying Therapies", Expert Opin. Investig. Drugs, (2003)12(3):325-35.  C8 Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellanc et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1198.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report, Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatchepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C18 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International	metros	C3	Barclay, "Hyperlipidemia", NMT Briefs, 2003.	I					
Copin Pharmacother, 2003 Nov;4(11):1901-38.  C6 Biller et al., "Isoprenoid (Phosphinyimethyl) Phosphonates as Inhibitors of Squalene synthetase", J. Med. Chem., 31 (10):1988, 1869-71.  C7 Bruckert, "New Lipid-Modifying Therapies", Expert Opin, Investig. Drugs, (2003)12(3):325-35.  C8 Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1198.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01:3095, 1-1-IX-11. 2001. Bethesda, MD. National Heart, Lung, and Blood Institute.  C15 Farrell., "Orugs and Steatohepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages). International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  International Search Report for Application No. PCT/US06/040639 dated May 23, 2007 (9 pages).  International Search Report for Application No. PCT/US06/040639 dated March 3, 2007 (8 pages).  International Search Report for Application No. PCT/US06/040640 dat	ососоруши	C4		-					
J. Med. Chem., 31 (10):1988, 1869-71.  C7 Bruckert, "New Lipid-Modifying Therapies", Expert Opin, Investig, Drugs, (2003)12(3):325-35.  C8 Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al., "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1196.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01:3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US06/040639 dated July 14, 2005 (7 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (8 pages).  C20 International Search Report for Application No. PCT/US06/040639 dated March 3, 2007 (8 pages).  C21 International Search Report for Application No. PCT/US06/040630 dated March 3, 2007 (8 pages).  C22 International Search Report for Application No. PCT/US06/040630 dated March 3, 2007 (8 pages).  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (	ancephone	C5	Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Pharmacother, 2003 Nov;4(11):1901-38.	Supply					
Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).  Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004, 64 (11): pp. 1181-1198.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD. National Heart, Lung, and Blood Institute.  C15 Farrelli, "Drugs and Steatohepatitis", Semin Liver Dis. (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl	NOTES PARCEL	C6		-					
C3 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004, 64 (11): pp. 1181-1198.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III Report. Publication number 01-3095, 1-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrelli, "Drugs and Steatohepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/040637 dated June 12, 2007 (8 pages).  C18 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040639 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040639 dated March 3, 2007 (8 pages).  C22 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C23 Kastelein J., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1998) 93(21):11991-11995.  C24 Kirkpatrick et al., "Market indicators", Nature, 2003, 2:98.		C7	Bruckert, "New Lipid-Modifying Therapies", Expert Opin. Investig. Drugs, (2003)12(3):325-35.	Ī					
C9 Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.  C10 Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.  C11 de Montellanc et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004, 64 (11): pp. 1181-1198.  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel! III Report. Publication number 01-3095, 1-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis. (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/040639 dated June 12, 2007 (8 pages).  C18 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated March 3, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040639 dated March 3, 2007 (8 pages).  C21 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C22 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C23 Kastelein J., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A. (1998) 93(21):11991-11995.  C24 Kirkpatrick et al., "Market indicators", Nature	000	C8		ſ					
C11 de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1198  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis, (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A. (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al., "Market indicators", Nature, 2003, 2:98.			Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.	Sammer and the same					
J. Med. Chem., (1977) 20:243-49.  C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1198  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis., (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelen J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al., "Market indicators", Nature, 2003, 2:98.	200	C10		L					
C12 Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.  C13 Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1196  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis, (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	Parace of Children	C11							
Developments", Drugs: 2004; 64 (11): pp. 1181-1198  C14 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis, (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Sirrivastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C23 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C24 Kirkpatrick et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A. (1998) 93(21):11991-11995.  C24 Kirkpatrick et al., "Market indicators", Nature, 2003, 2:98.		C12		ſ					
National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.  C15 Farrell., "Drugs and Steatohepatitis", Semin Liver Dis, (2002) 22(2):185-194.  C16 Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A. (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	Jacondonia	C13							
C16 Gagne, et al. "Efficacy and Safety of Exetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.		C14	National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number	-					
in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.  C17 International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).  C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.		C15	Farrell., "Drugs and Steatchepatitis", Semin Liver Dis, (2002) 22(2):185-194.	ľ					
C18 International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.		C16	in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-	Secretarion of the second					
pages).  C19 International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.		C17	International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).	ľ					
pages).  C20 International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.		C18	pages).	ACCOUNTS NO.					
pages).  C21 International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	C19		pages).						
pages).  C22 Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	***************************************	C20	pages).						
From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.  C23 Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50  C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	Bounage		pages).	1					
(134): pp. 45-50 C24 Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	770 market		From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.	-					
	V		(134): pp. 45-50	1					
/K.W/c25 Liao et al., "Blocking Microsomal Triglyceride Transfer Protein Interferes with apoB Secretion	*			L					

Examiner	/Kevin Weddington/	Date 1 10/09/2000	-
Signature	Wealth Areachiding	Considered 10/00/2003	8
Congridance		CONTROL CONTRO	

Substitute for form 1449/PTO					Complete If Known				
					Application Number	10/591,923-Conf. #5393			
INFORMATION DISCLOSURE				CLOSURE	Filing Date	September 5, 2006			
S.	TATE	MENT	3Y AF	PLICANT	First Named Inventor	Daniel J. Rader			
					Art Unit	1614			
	(Us	se as many sh	ets as ne	cess ary)	Examiner Name	Not Yet Assigned			
Sheet		5	of	5	Attorney Docket Number	AGP-002			
K.W./		Without Ca	using Re	tention or Stress in	the ER", Journal of Lig	pid Research, (2003) 44(5):978.	m		
9	C26			C.S., (1987) 109:55			m		
	C27			cyclic Ring Scaffold 2005, 3:3514-352		Cholesterol Absorption Inhibitors",			
	C28	C28 Robt et al, "A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors", Journal of Medicinal Chemistry, 2001, 44(6):851-856.							
	C29								
	C30	Sorbera, L.A., et al., Implitapide "Hypolipidemic Treatment of Atherosclerosis MTP Inhibitor ApoB Secretion Inhibitor", Drugs of the Future, (2000) 25(11):1138-1144.							
	C31								

Thomas et al., "Alleviation of MTP Inhibitor-Induced Hepatic Steatosis in Hyperlipidemic falfa

Rats by Fenofibrate", Dept. of Metabolic Diseases and Dept. of Chemical Research, Boehringer Ingetheim Pharma GmbH & Co. KG. (2005)

Wetterau et al., "An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels in WHHL

Wetterau et al., "Microsomal Triglyceride Transfer Protein", Biochimica Biophysica Acta, (1997)

Wierzbicki A.S., "New Lipid-Lowering Agents", Expert Opinion on Emerging Drugs, Ashley Publications, GB, 8 (2):2003, 365-376.

Drugs, 2002, 62(16):2333-2347.

1345(2):136-150.

Rabbits\*, Science, (1998) 282(5389):751-754.

LIBC/3095947v1

C32

C33

C34

/K.W./C35

Examiner		lDate	1 10/00/2000 I
LADITUIO	1 // a colon 144 and all and a con /	Date	10/00/7002
Signatura	I /Kevin Weddington/	Considered	10/00/=000
Sidnamia	I /INSVIII PYCUQIIQIQII/	(Considered	!
Signature	T TYANT MACAMUMININ	Lonsidered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.